Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,897 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03943004RecruitingPhase 1
Study drug DFP-14927 for advanced solid tumors
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT05983237RecruitingPhase 1/Phase 2
Fluzoparib, Camrelizumab, and Temozolomide for advanced melanoma
This trial tests a combination of three drugs (Fluzoparib, Camrelizumab, and Temozolomide) for people with advanced melanoma that has spread or cannot be removed by surgery. It is for those who have a specific genetic change (HR or SF3B1 mutation) and have not been treated with a PARP inhibitor before.
BeijingAges 18 years+ - NCT07347834Recruiting
Should you continue meds or have colitis surgery?
This trial studies whether continuing advanced medical treatments or having surgery (colectomy) is better for people with ulcerative colitis whose disease is active and hasn't improved after trying two or more advanced therapies.
Solna, Stockholm CountyAges 18 years+ - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07348965Recruiting
High-dose furmonertinib for EGFR-mutant lung cancer that spread to the brain lining
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
Guangzhou, GuangdongAges 18–75 - NCT07346248Enrolling by invitation
Complications after pre-surgery treatment for advanced rectal cancer
This study looks at complications that happen after surgery in patients with advanced rectal cancer who got radiation or chemo-radiation before their operation. Researchers want to learn how different pre-surgery treatments affect recovery.
Rozzano, MilanAges 18 years+ - NCT07347951RecruitingPhase 2
New drug combo for rectal cancer patients who want to save their anus
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
Wenzhou, ZhejiangAges 18–75 - NCT07343791RecruitingEarly Phase 1
DC-CIK cell therapy plus three drugs for advanced colorectal cancer
This trial tests a combination of immune cells (DC-CIK) and three cancer drugs (epaloliposide, vortexil, and regorafenib) as a third-line treatment for people with advanced colorectal cancer that has spread. It aims to see if this mix is safe and helps shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT07346183Recruiting
Text messages and peer support for dementia caregivers
This study tests a program that sends helpful texts and connects you with a trained peer caregiver who has been through similar experiences. It aims to make caring for someone with dementia easier and less stressful.
Chicago, IllinoisAges 18 years+ - NCT06069570RecruitingPhase 1
Gamma delta T cells and low dose radiation for advanced lung or bone cancer
This trial tests a new type of immune cell called gamma delta T cells combined with low-dose radiation to treat people with advanced lung cancer or solid tumors that have spread to the bone. It is only for patients who have already tried standard treatments and either didn't get better or couldn't tolerate them.
Tucson, ArizonaAges 18 years+ - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75 - NCT07339176RecruitingPhase 1/Phase 2
A trial of N17350 injected into tumors for advanced solid cancers
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT07337525RecruitingPhase 1
First study of PLT012 in advanced solid tumors
This trial tests a new drug called PLT012 for people with advanced solid tumors. It is the first study in humans, so doctors will see if the drug is safe and how the body handles it.
Los Angeles, CaliforniaAges 18 years+ - NCT07343349Recruiting
Adding a higher radiation dose to prostate tumors during standard radiotherapy
This trial tests whether giving an extra, focused dose of radiation to the visible tumor inside the prostate can improve results for men with intermediate or high-risk prostate cancer that has not spread. The total treatment is given in 12 or 20 sessions.
AarhusAges 18 years+ - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT07341815Recruiting
Support for parents with cancer and their children
This trial offers a talking support program to help parents with advanced cancer communicate better with their children aged 10 to 25. It focuses on open conversations about the illness and its impact on family life.
AnderlechtAges 18 years+ - NCT07340489RecruitingPhase 2
Serplulimab for locally advanced cervical cancer
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07340515RecruitingPhase 3
Proton vs standard radiation for advanced nasopharyngeal cancer
This trial is testing whether a newer, more precise type of radiation (proton therapy) works better than standard radiation (IMRT) for people with advanced nasopharyngeal cancer. It also includes chemotherapy and immunotherapy to see if the combination can improve outcomes.
Jinan, ShandongAges 18–70 - NCT06214949Recruiting
Personalized brain stimulation for chronic neck pain
This study tests if a personalized type of magnetic brain stimulation called PrTMS can help reduce chronic neck pain. It is for military health care beneficiaries who have had neck pain for at least 3 months.
Bethesda, MarylandAges 18–65 - NCT06730386RecruitingPhase 1
Trial of AK138D1 for advanced solid tumors
This trial tests a new drug called AK138D1 for people with advanced solid tumors that have not responded to or can't tolerate standard treatments. The goal is to see if it is safe and effective.
Blacktown, New South WalesAges 18–75 - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT06842095Recruiting
Stimulation therapy for stroke recovery
This trial tests if a non-invasive brain stimulation technique can improve arm movement recovery after a stroke. It is for people who had a stroke affecting their arm and are at least 3 months past the stroke.
OxfordAges 18 years+ - NCT07328425RecruitingPhase 2
A study of lurbinectedin and irinotecan for advanced DSRCT
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
Candiolo, TorinoAges 15 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,897 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.